Cipla joins hands with DNDi to formulate a medicine for HIV+ children
New Delhi, July 21, 2012: The Indian pharma major, Cipla today announced that the company has entered into collaboration with Drugs for Neglected Diseases Initiative (DNDi) to formulate a 4-in-1 anti-retroviral (ARV) medicine for children below three years of age infected with HIV. It is believed that this medicine will help accelerate care to the world’s youngest children living with AIDS or HIV.
It is estimated that close to 3.4 million children have HIV or AIDS but only less than 25% have the access to anti-retroviral therapy (ART) which is very low as compared to 54% adults who have the access to ART.
The company said that it is focusing on producing an appropriate 4-in-1 combination sachet product that can be easily mixed into food or liquids such as water, juice or breast milk.
Cipla aims to register the drug by the end of 2015 and being an industrial partner, it will be responsible for production, registration and distribution of the product. In fact, Cipla will retail all the intellectual property (IP) related to the new formulations.
Both the partners are expected to establish a detailed drug access and implementation plan in order to ensure timely delivery of the new product to patients. In a situation where Cipla moves out as an industrial partner, DNDi will be granted non-exclusive, worldwide, royalty-free licenses to the IP.